NBIX NEUROCRINE BIOSCIENCES INC

NEUTRAL Impact: 3/10 Insider Cluster (2 insiders)
Horizon weeks Filed May 29, 2026 Processed 7d 2h ago
Insider cluster: 2 insiders, $2.3M total

Price Chart

Loading chart...

Executive Summary

Two Neurocrine executives sold shares totaling $2.32M in the week following the close of the $2.9B Soleno acquisition. The CSO's sale of $1.71M was paired with a derivative exercise, while the Chief Corp. Affairs Officer sold $609K. Director grants on May 27 are non-cash compensation and carry no economic signal. The sales represent ~0.015% of market cap, well below the 0.1% materiality threshold, and are likely liquidity-driven following the acquisition close.

Key Financial Metrics

Direction
selling
Total Value
$2.3M
Insiders
2

Actionable Insight

The sales are routine post-acquisition liquidity events, not a bearish signal. The CSO's sale was fully hedged by derivative exercises (zero net economic exposure change). Director grants are standard compensation. No follow-up action warranted — monitor next 10-Q for integration progress on Soleno's VYKAT XR.

Key Facts

  • CSO Onyia Jude sold 11,000 shares at $155.53 for $1.71M on May 27, paired with derivative exercises (11,000 shares at $0 and 11,000 shares at $84.74)
  • Chief Corp. Affairs Officer Boyer sold 3,888 shares at $156.64 for $609K on May 26
  • Total open-market sales: $2.32M, representing ~0.015% of NBIX's $15.7B market cap
  • 11 directors received non-cash stock grants on May 27 totaling ~29,000 shares at $0 — routine compensation, no economic signal
  • Sales occurred 9 days after the May 18 close of the $2.9B Soleno acquisition

Financial Impact

Total insider sales of $2.32M represent ~0.015% of market cap — immaterial relative to company size

dilution

Risk Factors

  • Post-acquisition integration risk for Soleno's VYKAT XR (Prader-Willi syndrome) could pressure near-term earnings
  • Additional $600M drawn on $1.0B credit facility increases leverage, though manageable for a $15.7B market cap company

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (35 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-NBIX-1780092662734
11 reports for NBIX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for NBIX — sortable, filterable
Type Now
Jun 4, 2026
1d ago
Insider Cluster
NEUTRAL ★ 3/10
awaiting T+1
Jun 2, 2026
3d ago
Insider Cluster
NEUTRAL ★ 2/10
$164.23 $166.83▲ +1.58%▲ +1.18%$163.88 (−0.21%)
Jun 2, 2026
3d ago
Insider Cluster
NEUTRAL ★ 3/10
awaiting T+1
Jun 2, 2026
3d ago
Insider Cluster
NEUTRAL ★ 2/10
awaiting T+1
May 29, 2026
7d ago
Insider Cluster
NEUTRAL ★ 3/10
awaiting T+1
May 28, 2026
8d ago
Insider Cluster
NEUTRAL ★ 4/10
awaiting T+1
May 21, 2026
15d ago
Insider Cluster
NEUTRAL ★ 4/10
awaiting T+1
May 21, 2026
15d ago
Insider Cluster
BEARISH ★ 5/10
awaiting T+1
May 18, 2026
18d ago
Insider Cluster
NEUTRAL ★ 3/10
awaiting T+1
May 18, 2026
18d ago
8-K
BULLISH ★ 7/10
awaiting T+1
Showing 10 of 11

US Market Status

Market Closed — Opens Mon (36h 25m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access